Register to join the KCSN
Menu

European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of the combination of avelumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This recommendation is based on findings from the phase III JAVELIN Renal 101 study involving 886 patients, which demonstrated significant improvements in median […]

Sep 20, 2019 / Comments Off on European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer / / Tags: , , , , , , , , ,
read more

Steve Pointon launches his 40 for 40 fundraising challenge

Please get behind Steve to support him during his 40 days of fitness before he turns 40! All donations will help support KCSN and The Christie Hospital in Manchester and are very much appreciated! Please donate via JustGiving or visit the KCSN website here Read about Steve’s challenge in Stoke-on-Trent Live here

Sep 16, 2019 / Comments Off on Steve Pointon launches his 40 for 40 fundraising challenge / / Tags: , ,
read more

Tivozanib in heavily pre-treated advanced kidney cancer patients

Further data from the TIVO-3 clinical trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma (RCC), which is unresponsive to treatment (refractory), has shown that at 32.5 months, 20 patients on tivozanib remain progression free, versus 2 patients on sorafenib. This is despite there being no positive effect on overall survival (median […]

Sep 16, 2019 / Comments Off on Tivozanib in heavily pre-treated advanced kidney cancer patients / / Tags: , , , , , ,
read more

PD-L1 expression and clinical outcomes with targeted therapy

A recent study published in Clinical Cancer Research analysed tumour tissue samples obtained in a clinical trial to investigate how the expression of the PD-L1 receptor on the tumour cells influenced outcomes in patients with metastatic renal cell carcinoma (RCC) receiving targeted therapy. Positive expression of the PD-L1 receptor on RCC tumour cells was associated […]

Sep 16, 2019 / Comments Off on PD-L1 expression and clinical outcomes with targeted therapy / / Tags: , , , , , , , ,
read more

Immune checkpoint inhibitors are more effective in PD-L1 positive patients

Immune checkpoint inhibitors, such as nivolumab, ipilimumab or pembrolizumab are often used alone or in combination with other drugs for the treatment of metastatic renal cell carcinoma (RCC). Unfortunately, researchers are yet to identify a reliable biomarker to predict a patient’s response to immune checkpoint inhibitors. PD-L1 is a potential biomarker for the effectiveness of […]

Sep 11, 2019 / Comments Off on Immune checkpoint inhibitors are more effective in PD-L1 positive patients / / Tags: , , , , , ,
read more

Ilixadencel plus sunitinib combination for metastatic kidney cancer

A combination of ilixadencel plus sunitinib has shown a complete tumour response in patients with metastatic renal cell carcinoma (RCC) in a recent phase 2 clinical trial. Ilixadencel is an off-the-shelf immune primer for the treatment of solid tumours. The clinical trial assessed the effectiveness of combining ilixadencel with sunitinib in 88 untreated patients with […]

Sep 10, 2019 / Comments Off on Ilixadencel plus sunitinib combination for metastatic kidney cancer / / Tags: , , , , ,
read more

Personalised immunotherapy for advanced kidney cancer

In this video interview, Dr David Braun from the Dana-Farber Cancer Institute in Boston, USA, discusses his innovative research in metastatic kidney cancer, which focuses on understanding and improving immunotherapies in kidney cancer. He is working to develop novel immune-based treatments to personalise immunotherapy to overcome resistance to treatment. His work aims to better understand […]

Sep 05, 2019 / Comments Off on Personalised immunotherapy for advanced kidney cancer / / Tags: , , , , , ,
read more

European Commission approves pembrolizumab plus axitinib combination for first-line treatment of advanced kidney cancer

Based on the findings from the pivotal phase 3 KEYNOTE-426 trial, the European Commission has today approved pembrolizumab (anti-PD-1 therapy) in combination with axitinib (tyrosine kinase inhibitor) for patients with untreated, advanced renal cell carcinoma (RCC). The KEYNOTE-426 trial demonstrated a reduced risk of death by 47% with the combination compared to sunitinib in patients […]

Sep 04, 2019 / Comments Off on European Commission approves pembrolizumab plus axitinib combination for first-line treatment of advanced kidney cancer / / Tags: , , , , , , , ,
read more

Right-sided kidney tumours have better outcomes

In a recent paper published in Cancer Medicine from researchers in Boston, USA, people with a large (10 cm or larger) renal cell carcinoma (RCC) tumour on their right kidney had a significant 15% decreased risk of death and better cancer-specific survival than left-sided RCC. Read more in Renal & Urology News here

Aug 29, 2019 / Comments Off on Right-sided kidney tumours have better outcomes / / Tags: , , ,
read more
Showing 1 to 10 of 456 results
Douglass Digital Logo Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
  TOP